enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update
by Danessa Lincoln · The Markets DailyenGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) was the recipient of a large decrease in short interest in February. As of February 27th, there was short interest totaling 7,709 shares, a decrease of 21.7% from the February 12th total of 9,849 shares. Based on an average daily trading volume, of 3,318 shares, the short-interest ratio is presently 2.3 days. Based on an average daily trading volume, of 3,318 shares, the short-interest ratio is presently 2.3 days.
enGene Trading Up 1.6%
Shares of NASDAQ:ENGNW traded up $0.04 during trading on Tuesday, reaching $2.50. The company had a trading volume of 3,067 shares, compared to its average volume of 20,024. The firm’s fifty day moving average is $3.09 and its 200 day moving average is $2.32. enGene has a twelve month low of $0.51 and a twelve month high of $4.20.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.